Helping People with Diabetes Block the Bad Carbs
WALTHAM, Mass., Oct. 7, 2013 /PRNewswire/ -- Those who treat people with type 2 diabetes know that making a conscious effort to change lifestyle habits shows the best outcomes. Unfortunately, there are challenges to cutting intake of foods with fat and refined sugar.
Before resorting to extreme measures, people with type 2 diabetes may want to note the encouraging news coming out of Manchester, New Hampshire. The city is home base of Boston Therapeutics, Inc., an innovative pharmaceutical company working on complex carbohydrate compounds to help people concerned about blood sugar moderate their blood glucose levels after eating carbohydrates.
The investigational treatment is a chewable tablet, locally acting complex carbohydrate-based compound, PAZ320, a new chemical entity that is taken right before a meal and designed to lower the rise of blood sugar that occurs after eating. PAZ320 could prevent, or at least delay, the onset of type 2 diabetes and a host of related complications ranging from heart disease to diabetic foot. The compound works in the gut by blocking the action of carbohydrate hydrolyzing enzymes that break down carbs in foods during digestion.
Researchers have already tested PAZ320 in patients with type 2 diabetes and obtained positive results. In a study conducted at Dartmouth Medical Center, 45 percent of patients responded to PAZ320 with a significant 40 percent reduction of post-meal glucose in the blood compared with the baseline. Additionally, results showed the effect of PAZ320 works regardless of whatever other diabetes medications one is taking. And there were no serious side effects.
A drug like PAZ320--even if approved for commercial use--is only one small tool in the fight against diabetes. There are many other strategies to keep symptoms at bay. But such a pill could provide another tactical weapon in the arsenal against a problem whose incidence is exploding.
For more on this exciting advance, visit www.bostonti.com.
Contact: Susan Forman, Dian Griesel Int'l., 212.825.3210
SOURCE Boston Therapeutics, Inc.